Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novimmune, Baxalta Ink Bispecific Antibody Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Novimmune, Baxalta Ink Bispecific Antibody Pact

Will use Novimmune's new kappa-lambda bispecific antibody technology platform

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novimmune SA has signed an international research collaboration with Baxalta to develop novel bispecific antibodies for an undisclosed indication. Financial terms were not disclosed.
 
The collaboration will use Novimmune’s new kappa-lambda bispecific antibody technology, a platform that generates fully human antibodies that target two specific binding sites with one antibody.
 
“The kappa-lambda platform is exactly the right technology for therapy areas which need a bispecific antibody that is as close to a natural human antibody as you can get,” said Novimmune chief executive officer Jack Barbut. Bispecific antibodies currently used in biopharmaceutical applications have been constructed using chemical linkers, non-human material, antibody fragments or forced engineering, he said.
 
“Our kappa-lambda antibodies are allowed to assemble naturally,” said head of Research Nicolas Fischer. “So, they have promising development and safety characteristics such as a longer half-life, increased stability and a lower risk of provoking an unwanted reaction in patients.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics